BlackRock Fund Advisors recently announced the acquisition of new stake in Abbott Laboratories (NYSE:ABT). The institutional investor has increased its shareholding in the Healthcare company by 1.96% to 89.35 million shares with purchase of 1.72 million shares. This fresh investment now brings its stake to 5.15% valued currently at $9.83 billion. In addition, Capital Research & Management Co raised its holdings by 1.84 million to 79.06 million shares. And Capital Research & Management Co has lifted its position by 6.18% or 3.66 million shares – to 62.84 million shares.
Currently, there are 1.74B common shares owned by the public and among those 1.72B shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 94 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 39 of these insider trades were purchases, accounting for 388,626 shares. Insider sales of the common stock occurred on 55 occasions, with total insider shares sold totaling 343,931 shares.
The top 3 mutual fund holders in Abbott Laboratories are Vanguard Total Stock Market ETF, Vanguard 500 Index Fund, and American Funds Investment Company. Vanguard Total Stock Market ETF owns 54.51 million shares of the company’s stock, all valued at over $6.0 billion. The company bought an additional 0.1 million shares recently to bring their total holdings to about 3.14% of the shares outstanding. Vanguard 500 Index Fund bought 79749.0 shares to see its total holdings expand to 42.38 million shares valued at over $4.66 billion and representing 2.44% of the shares outstanding. American Funds Investment Company bought 4.12 million shares to bring its total holdings to over 26.75 million shares at a value of $2.94 billion. American Funds Investment Company now owns shares totaling to 1.54% of the shares outstanding.
However, the script later moved the day high at 113.47, up 1.29%. The company’s stock has a 5-day price change of -0.65% and 20.72% over the past three months. ABT shares are trading 3.07% year to date (YTD), with the 12-month market performance up to 2.14% higher. It has a 12-month low price of $89.67 and touched a high of $115.83 over the same period. ABT has an average intraday trading volume of 5.46 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.92%, 5.26%, and 8.42% respectively.
Institutional ownership of Abbott Laboratories (NYSE: ABT) shares accounts for 75.62% of the company’s 1.74B shares outstanding. Mutual fund holders own 4.27%, while other institutional holders and individual stakeholders account for 42.63% and 33.25% respectively.
It has a market capitalization of $196.96B and a beta (3y monthly) value of 0.74. The stock’s trailing 12-month PE ratio is 34.74, while the earnings-per-share (ttm) stands at $3.27. The company has a PEG of 4.45 and a Quick Ratio of 1.23 with the debt-to-equity ratio at 0.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.04% over the week and 1.36% over the month.
Analysts forecast that Abbott Laboratories (ABT) will achieve an EPS of $Abbott Laboratories for the current quarter, $113.45 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Arbor Realty Trust while analysts give the company a high EPS estimate of $American Tower Corporation (REI. Comparatively, EPS for the current quarter was $AdvisorShares Vice ETF a year ago. Earnings per share for the fiscal year are expected to increase by 4.16%, and 11.42% over the next financial year. EPS should shrink at an annualized rate of 7.80% over the next five years, compared to 19.74% over the past 5-year period.
